# US 2018/0021275 A1 · Method of treating idiopathic pulmonary fibrosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021275 A1
- Document ID: US20180021275A1
- Status: Published application
- Kind: A1
- Application number: 15/642,316
- Filed: 2017-07-05
- Published: 2018-01-25
- Earliest claimed: 2014-05-08
- Assignees: MediciNova, Inc.
- Applicants: MediciNova, Inc.
- Inventors: Kazuko MATSUDA; Yuichi IWAKI
- Web page: https://patentgrep.com/patent/US20180021275A1

## CPC

- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61P 11/00: Drugs for disorders of the respiratory system
- C07C 59/90: containing singly bound oxygen-containing groups
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

A compound of Formula (I): or a metabolite thereof, or an ester of the compound of Formula (I) or the metabolite thereof, or a pharmaceutically acceptable salt of each thereof, wherein m, n, X1 and X2 are as defined herein, is useful for inhibiting or treating idiopathic pulmonary fibrosis, conditions leading to or arising from it, and/or negative effects of each thereof.

## Claims

### Claim 1

A method of treating a patient diagnosed with idiopathic pulmonary fibrosis (IPF), the method comprising administering to the patient an effective amount of a compound of Formula (I), a metabolite of the compound of Formula (I), an ester of the compound of Formula (I), or a metabolite of the ester of the compound of Formula (I):
or a pharmaceutically acceptable salt of each of the foregoing, wherein m is an integer from 2 to 5 inclusive, and n is an integer from 3 to 8 inclusive, X1 and X2 each independently represent sulfur, oxygen, a sulfinyl group or a sulfonyl group, provided that X1 and X2 are not simultaneously oxygen, wherein the effective amount of the compound is about 100 mg to about 4000 mg/day.

### Claim 2 (depends on 1)

The method of claim 1, wherein the compound of Formula (I) is of Formula (IA)

### Claim 3 (depends on 1)

The method of claim 1, wherein the metabolite of the compound of Formula (I) is a compound of Formula (IB):

### Claim 4 (depends on 1)

The method of claim 1, wherein the compound is administered orally.

### Claim 5 (depends on 4)

The method of claim 4, wherein the compound is administered as a tablet or a capsule.

### Claim 6 (depends on 2)

The method of claim 2, wherein the compound is present in an orthorhombic crystalline polymorphic form.

### Claim 7 (depends on 1)

The method of claim 1, wherein the compound is administered as a liquid dosage form.

### Claim 8 (depends on 1)

The method of claim 1, wherein the effective amount of the compound is administered in an amount from about 250 to about 2,000 mg/day, divided into one, two, or three portions.

### Claim 9 (depends on 1)

The method of claim 1, wherein the patient's pulmonary scarring is inhibited.

### Claim 10 (depends on 1)

The method of claim 1, wherein the patient's elevated lung hydroxyproline levels are reduced and/or inhibited.

### Claim 11 (depends on 1)

The method of claim 1, wherein the patient's elevated lung density is reduced.

### Claim 12 (depends on 1)

The method of claim 1, wherein the patient's elevated total cell count (TCC) in bronchioalveolar lavage fluid (BALF) is reduced.

### Claim 13

A method of treating a patient diagnosed with IPF, the method comprising administering to the patient an effective amount of a compound of Formula (IA), a metabolite of the compound of Formula (IA), an ester of the compound of Formula (IA), or a metabolite of the ester of the compound of Formula (IA):
or a pharmaceutically acceptable salt of each of the foregoing, wherein the effective amount of the compound is about 100 mg to about 4000 mg/day.

### Claim 14 (depends on 13)

The method of claim 13, wherein the compound is administered orally.

### Claim 15 (depends on 13)

The method of claim 13, wherein the compound is administered as a tablet or a capsule.

### Claim 16 (depends on 13)

The method of claim 13, wherein the compound is administered as a liquid dosage form.

### Claim 17 (depends on 13)

The method of claim 13, wherein the compound is administered in an amount from about 250 to about 2,000 mg/day, divided into one, two, or three portions.

### Claim 18 (depends on 13)

The method of claim 13, wherein the patient's pulmonary scarring is inhibited.

### Claim 19 (depends on 13)

The method of claim 13, wherein the patient's elevated lung hydroxyproline levels are reduced and/or inhibited.

### Claim 20 (depends on 13)

The method of claim 13, wherein the patient's elevated lung density is reduced.

### Claim at position 21

21-30. (canceled)
